INFLUENCE OF FUSARIC ACID ON URINARY EXCRETION OF CATECHOLAMINES; A CLINICAL STUDY WITH PARTICULAR EMPHASIS ON THE CHARACTERISTICS OF ITS TIME-COURSE CHANGE
スポンサーリンク
概要
- 論文の詳細を見る
To 10 hypertensive patients fusaric acid, a dopamine-β-hydroxylase inhibitor, was administered orally in daily dose of 300-600 mg for 4 weeks, and the change of urinary catecholamines was examined almost every day. The results obtained were as follows. (1) There were three patterns of the time-course change in the urinary excretion of noradrenaline during the fusaric acid therapy, i.e., (i) that of "initial spike-like increase followed by a continuous increase throughout the later stage", found in 3 cases receiving 300 mg/day dose and I case receiving 600 mg/day, (ii) that of "late rise", i.e. a continuous rise throughout the later stage, seen in 4 cases receiving 300 mg/day, and (iii) that of "minimal change", seen in 2 cases receiving 600 mg/day. These observations formed a sharp contrast with the fact that, during the administration of reserpine, urinary noradrenaline excretion was moderately to severely decreased. (2) Urinary adrenaline excretion did not change with the administration of fusaric acid. (3) No definite relation was found between the cnages in urinary noradrenaline excretion and changes in blood pressure during the fusaric acid therapy . In conclusion, it is suggested that a small amount of fusaric acid (300 mg/day for adults), administered orally, causes noradrenaline to be released and noradrenaline biosynthesis to be accelerated later. With larger doses (600 mg/day), ho*Never, this trend was not conspicuous.
- 社団法人日本循環器学会の論文
- 1973-01-20